Edison Goncalves, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1457309593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,112 of the $141,918 with a category attached, or 89.6%. Novo Nordisk accounts for 94.5% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $71,256 and has fallen 99.4% since, to $451 in 2025. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 507 payments — averaging $279.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$134K
- Johnson & Johnson$3K
- AstraZeneca$750
- Corcept Therapeutics$560
- Dexcom, Inc.$504
- Sanofi-aventis U.S. LLC$375
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$127,11290%
- Travel & lodging$5,5044%
- Food & beverage$9,2116%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 250 | $134,124 |
| Johnson & Johnson | 17 | $2,844 |
| AstraZeneca | 32 | $750 |
| Corcept Therapeutics | 28 | $560 |
| Dexcom, Inc. | 26 | $504 |
| Sanofi-aventis U.S. LLC | 22 | $375 |
| Abbott | 15 | $326 |
| Novartis | 20 | $276 |
| AbbVie | 15 | $266 |
| Boehringer Ingelheim | 5 | $207 |
| Amgen(2 entities) | 12 | $184 |
| Merck | 5 | $167 |
| Lilly USA, LLC | 9 | $158 |
| Medtronic(2 entities) | 7 | $143 |
| Kowa Pharmaceuticals America, Inc. | 2 | $132 |
| IBSA Pharma Inc. | 7 | $131 |
| Mannkind Corporation | 7 | $122 |
| Tandem Diabetes Care, Inc. | 6 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| BETA Bionics, Inc. | 5 | $106 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Antares Pharma, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $40 |
| Radius Health, Inc. | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Bayer | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,918 in reported general payments places this provider in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 428 | $535,025 |
| MounjaroTirzepatide | 162 | $189,636 |
| JardianceEmpagliflozin | 211 | $185,713 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 107 | $102,882 |
| FarxigaDapagliflozin Propanediol | 52 | $57,593 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $42,488 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $38,281 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $31,835 |
| TrulicityDulaglutide | 25 | $30,074 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $23,450 |
| Victoza 3-PakLiraglutide | 13 | $21,733 |
| SynthroidLevothyroxine Sodium | 224 | $19,295 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $19,072 |
| JanuviaSitagliptin Phosphate | 15 | $18,623 |
| Humalog Kwikpen U-100Insulin Lispro | 71 | $17,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $134,124 | $543,363446 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $207 | $298,198333 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $158 | $227,567224 claims |
| AstraZenecaFarxiga | $750 | $57,59352 claims |
| AbbVieSynthroid | $266 | $19,295224 claims |
| MerckJanuvia | $167 | $18,62315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $9,710755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.